Nearly 200 million people are affected by malaria each year according
to the WHO. Though deadly, the disease is preventable and curable as
long as it is diagnosed early enough for medical treatment to begin. New
developments are constantly being made on that front, but the latest
breakthrough device could be a complete game-changer in the fight
against the deadly disease.
John Lewandowski is a PhD student at MIT, where he invented a
groundbreaking new device that could have a dramatic impact on the way
heath care professionals combat malaria. His creation is called the RAM,
which stands for Rapid Assessment of Malaria, and it’s a small box
capable of diagnosing malaria accurately in just 5 seconds.
“Early detection is very important, typically in the first five to
seven days before symptoms arise, so that treatment can begin,” the
26-year-old scientist recently told CNNMoney.
There are currently two ways to diagnose the deadly disease, both
requiring blood analysis. A blood sample can be analyzed by human eyes
under a microscope in order to determine whether or not the parasite is
present, or a diagnostic test can be used. The latter is preferential,
especially in the field, but the current crop of devices often have
difficulty detecting early-stage infections.
With a single drop of blood, Lewandowski’s RAM device can accurately
detect the presence of malaria using Magneto-Optical Detection as
early as a week before symptoms even present themselves. Like a
pregnancy test, the RAM analyzes the sample and returns either a
positive or negative response.
As impressive as the technology itself is the cost to
build Lewandowski’s creation, which is assembled from parts that cost
less than $120 all together. Beyond the outer box and LCD display, the
RAM consists mainly of a circuit board, a laser, some magnets and an SD
card reader.
The RAM is currently being developed by Boston-based Disease Diagnostic Group,
a company Lewandowski founded to create and distribute the RAM. A
recent filed test in India yielded results that were accurate 93% to 97%
of the time, and the company will launch a new field trial this summer
in Nigeria that Lewandowski hopes will test as many as 5,000 patients
Source: Click here
Subscribe to:
Post Comments
(
Atom
)


0 comments:
Post a Comment